BioSpace News Archive

Hagens Berman Sobol Shapiro LLP reminds investors in Weight Watchers International, Inc. of the May 3, 2019 Lead Plaintiff deadline in the pending securities class action.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Thursday, April 25, 2019, after market close, the Company will release first quarter 2019 results.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.

Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania

Dr. Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company for one year

Nobilis Health Corp. announced that it has submitted a formal request with the NYSE to extend the Company’s deadline for filing its Q3 2018 financials.

KEYTRUDA Now Approved for First-Line Treatment of Patients with Stage III NSCLC Who Are Not Candidates for Surgical Resection or Definitive Chemoradiation, or Metastatic NSCLC, and Whose Tumors Express PD-L1 (TPS ≥1%), with No EGFR or ALK Genomic Tumor Aberrations

Data presented in Late-Breaking Presentation at the EASL International Liver Congress™ [11-April-2019] SAN FRANCISCO and HERZLIYA, Israel , April 11, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced that preclinical data of its investigat

PetaGene, provider of state of the art compression technology for genomic data, today announced the addition of PetaSuite Protect to its award winning range of genomic data products.